Immuron (IMRN) Non-Current Assets (2016 - 2025)
Immuron (IMRN) posted quarterly Non-Current Assets of $1146.2 for Q3 2025, down 86.08% year-on-year from $8236.3 in Q3 2024, and down 98.58% on a QoQ basis from $80944.6 in Q2 2025.
Immuron (IMRN) Non-Current Assets (2016 - 2025) Analysis & Trends
Immuron (IMRN) has reported Non-Current Assets for 10 consecutive years, with $1146.2 the latest figure, recorded in Q3 2025.
- Quarterly Non-Current Assets fell 86.08% year-over-year to $1146.2 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $382993.0 (down 77.62% YoY) and the FY2025 annual result came in at $1146.2, down 86.08% from the prior year.
- Non-Current Assets slipped to $1146.2 in Q3 2025 per IMRN's latest filing, from $80944.6 in the prior quarter.
- Over the last five years, Non-Current Assets for IMRN reached as high as $1.1 million in Q3 2023 and fell as low as -$18.0 million in Q4 2021.
- A 5-year average of -$827476.4 and a median of $437167.6 in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets slumped 101378.16% — and 2024, when it jumped 4327.08%.
- Year by year, Non-Current Assets stood at -$18.0 million in 2021, then jumped by 104.64% to $835938.4 in 2022, then tumbled by 99.21% to $6610.8 in 2023, then soared by 4327.08% to $292665.9 in 2024, then plunged by 99.61% to $1146.2 in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $1146.2, $80944.6, and $292665.9 for Q3 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - | 1,146.16 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 1,146.16 |
| Jun 30, 2025 | 80,944.65 |
| Dec 31, 2024 | 292,665.86 |
| Sep 9, 2024 | 8,236.32 |
| Jun 30, 2024 | 581,669.24 |
| Dec 31, 2023 | 6,610.81 |
| Sep 28, 2023 | 1.12 Mn |
| Aug 30, 2023 | -204,093.37 |
| Jun 30, 2023 | 1.12 Mn |
| Dec 31, 2022 | 835,938.37 |
| Aug 31, 2022 | 835,938.37 |
| Jun 30, 2022 | 835,938.37 |
| Dec 31, 2021 | -18.01 Mn |
| Jun 30, 2021 | 918,323.72 |
| Dec 31, 2020 | 17,780.76 |
| Sep 1, 2020 | -4.41 Mn |
| Jun 30, 2020 | 1.27 Mn |
| Dec 31, 2019 | 17,931.22 |
| Jun 30, 2019 | 1.88 Mn |
| Dec 31, 2018 | 646,638.00 |